PixCell Medical
PixCell Medical is an Israeli medical device company that develops and markets HemoScreen, an FDA-cleared portable point-of-care CBC analyzer using proprietary Viscoelastic Focusing microfluidics and AI-powered machine vision to deliver lab-quality blood diagnostics in five minutes from a single drop.
- Company typePrivate
- Founded2009
- HeadquartersYoqne`am `illit, Israel
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What PixCell Medical does
PixCell Medical Technologies Ltd. is an Israel-based, privately held medical device company founded in 2009 and headquartered in Yokneam Ilit, with a US subsidiary in Longmont, Colorado. The company develops, manufactures, and commercializes the HemoScreen, a portable point-of-care Complete Blood Count (CBC) analyzer that delivers 20 CBC parameters including a 5-part differential from a single drop of blood in approximately five minutes. The platform is built on three proprietary technology pillars: Viscoelastic Focusing (VEF) microfluidics—protected by over 30 patents and discovered at Technion–Israel Institute of Technology—a single-use Lab-On-A-Cartridge with factory-calibrated reagents and contained sample handling, and AI-powered machine-vision classification of cells by morphology and staining. HemoScreen is FDA 510(k)-cleared as the only 5-part differential CBC analyzer cleared for Point of Care use, CE-marked, and classified as CLIA moderate-complexity, and it requires no maintenance, calibration, or specialized operator.
The business model is a classic razor-and-blade: capital sale of the portable HemoScreen reader plus recurring revenue from single-use cartridges consumed per test. PixCell commercializes primarily through a global distributor network—Katalyst Diagnostics (UK/Ireland), Werfen (Spain/Portugal), BioMed (Italy), BIOKOSMOS (Greece), Axonlab (Switzerland/Austria/Netherlands/Czech Republic), SoulBrain (South Korea), Alatheia (Chile), Point of Care Diagnostics (Australia/NZ), and Healthcare Technologies (South Africa)—combined with US distribution through Thermo Fisher Scientific, Henry Schein Medical Group, and Medline Industries, plus enterprise direct sales via a "Request a Demo" motion. End customers span emergency departments, urgent care clinics, oncology and hemato-oncology services, mental health (clozapine) clinics, primary care, pediatrics, blood banks, and military/field operations, with named deployments across NHS trusts in England, university hospitals in Sweden and Denmark, and clinics in Israel, Chile, Australia, and the US.
PixCell is led by co-founder and CEO Avishay Bransky, Ph.D., with a CCO, COO, CFO, dedicated US sales leadership, and a board that includes strategic investor Soulbrain Holdings representatives (Co-Chairman Nam Huh and Director Jongkook Park). Disclosed capital is modest: a 2018 EISMEA-linked raise of approximately $4.4M and a 2022 International Health-Tech Pilot Program grant. The company has signaled continued expansion through the 2020 Interreg Germany-Denmark Changing Cancer Care partnership for home-based cancer patient testing and the 2022 Charité Krankenhaus / Berlin Institute of Health collaboration for new clinical applications.
PixCell Medical firmographics
Firmographics- Name
- PixCell Medical
- Legal name
- PixCell Medical Technologies Ltd.
- Website
- https://pixcell-medical.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- PixCell Medical is an Israeli medical device company that develops and markets HemoScreen, an FDA-cleared portable point-of-care CBC analyzer using proprietary Viscoelastic Focusing microfluidics and AI-powered machine vision to deliver lab-quality blood diagnostics in five minutes from a single drop.
- Ownership category
- akta.pro rank
PixCell Medical industry classification
Industry- Product category
- Point-of-Care Hematology Analyzers
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Hematology POCT (CBC/hemoglobin/hematocrit) (HLAHAOAD)
- akta.pro secondary industries
- Flow Cytometry & Cellular Analysis Diagnostics (HLAHAAAF), Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)
Keywords
Where PixCell Medical is headquartered
LocationHeadquarters
- HQ city
- Yoqne`am `illit
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
PixCell Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- HemoScreen Analyzer Hardware: Sale of the portable point-of-care hematology analyzer device
- Single-Use Cartridges: Disposable cartridges with integrated reagents for each test. Per-test payment model. Each cartridge includes all required reagents and is factory-calibrated.
Go-to-market motion2 records
Distribution channels13 records
Marketing channels5 records
PixCell Medical product offering
Product offeringCore offering
PixCell Medical develops, manufactures, and markets the HemoScreen™ platform, a portable point-of-care hematology analyzer that performs a Complete Blood Count (CBC) with 5-part differential from a single drop of blood in approximately 5 minutes. The system consists of a reusable analyzer device and single-use factory-calibrated cartridges with integrated reagents, combining proprietary Viscoelastic Focusing (VEF) microfluidics, Lab-On-A-Cartridge design, and AI-powered machine vision for automated cell classification.
Product overview
PixCell Medical offers a single core product platform: the HemoScreen™ system, which consists of a portable hematology analyzer device and single-use cartridges. The platform performs Complete Blood Count (CBC) testing with 5-part differential at the point of care in approximately 5 minutes. The technology combines Viscoelastic Focusing (VEF) microfluidics, Lab-On-A-Cartridge design, and AI-powered machine vision for automated cell classification. The system delivers 20 standard CBC parameters and requires no maintenance, calibration, or reagent handling. Clinical settings include primary care, emergency medicine, oncology, pediatrics, blood centers, and military/field use.
Differentiator
Problem solved
Functional benefit
Brands
- HemoScreen™: FDA-cleared portable Point of Care Complete Blood Count (CBC) analyzer with 5-part differential, using Viscoelastic Focusing (VEF) technology and AI-based machine vision analysis.
Products and services
- HemoScreen™ Hematology Analyzer Portable, FDA-cleared point-of-care Complete Blood Count (CBC) analyzer with 5-part differential for hospitals, urgent care clinics, oncology centers, primary care, mental health clinics, pediatrics, blood banks, and military/field use. Requires no maintenance, no calibration, and minimal training.
- HemoScreen™ Single-Use Test Cartridges Disposable, factory-calibrated Lab-On-A-Cartridge consumables containing all required reagents for a CBC test; sealed to prevent cross-contamination and operated on a per-test payment model alongside the HemoScreen analyzer.
Quantifiable outcome
- Results delivered in 5 minutes compared to 20+ minutes longer turnaround time in clinical labs
- +3 more outcomes
Companies that use PixCell Medical
Customer profileNamed customers11 records
Segments7 records
Ideal customer profiles4 records
PixCell Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
PixCell Medical partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and flagship.
- Charité KrankenhauscoreCollaboration with Charité Krankenhaus and Berlin Institute of Health under the International Health-Tech Pilot Program grant to develop new applications for the HemoScreen hematology analyzer and improve global patient care through international cooperation and technology validation.
- Berlin Institute of HealthcoreCollaboration with Charité Krankenhaus and Berlin Institute of Health under the International Health-Tech Pilot Program grant to develop new applications for the HemoScreen hematology analyzer and validate innovative medical technologies through international cooperation.
- Interreg Germany-Denmark Changing Cancer Care (CCC)flagshipFlagship partnership to enable home-based blood testing for cancer patients in homecare settings, limiting immunocompromised patients' exposure to contagion in hospitals. Cancer patients in Denmark were trained to use HemoScreen to perform 5-part CBC tests to manage their treatments and support clinical decision-making.
- Katalyst DiagnosticscoreUK & Ireland distributor of HemoScreen products
- WerfencoreSpain & Portugal distributor of HemoScreen products
- BioMed SrlcoreItaly distributor of HemoScreen products
- BIOKOSMOS MORIAKI S.A.coreGreece distributor of HemoScreen products
- AxonlabcoreSwitzerland, Austria, Netherlands, and Czech Republic distributor of HemoScreen products
- Thermo Fisher ScientificflagshipUS distribution partner for HemoScreen products - one of the world's largest distributors of laboratory and medical equipment
- Henry Schein Medical GroupflagshipUS distribution partner for HemoScreen products - leading provider of health care products and services to physicians and practices
- Medline IndustriesflagshipUS distribution partner for HemoScreen products - largest privately held manufacturer and distributor of medical supplies in the US
- AlatheiacoreChile distributor of HemoScreen products
- SoulBrainflagshipSouth Korea distributor of HemoScreen products - also serves as a Board member through Soulbrain Holdings (Nam Huh, Ph.D., Co-Chairman and Director)
- Point of Care DiagnosticscoreAustralia & New Zealand distributor of HemoScreen products
- Healthcare TechnologiescoreSouth Africa distributor of HemoScreen products
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
PixCell Medical competitors and assessment
Company assessmentBroad incumbents
- Siemens Healthineers: Markets the Atellica/ADVIA hematology lines for core labs and is actively pushing decentralized diagnostics. Broad incumbent with the breadth to bundle POC CBC with broader diagnostics portfolios.
- Beckman Coulter (Danaher): Major clinical hematology franchise (DxH 900, DxH 500) within Danaher's Diagnostics platform. Broad incumbent offering overlapping CBC capability with the scale to launch a competing POC analyzer if economics warrant.
- Sysmex Corporation: World-leading hematology analyzer company (XN-Series, pocH-100i) dominating hospital and reference-lab CBC. Broad incumbent whose installed base and scale could rapidly move into POC hematology if category adoption accelerates.
- Abbott Point of Care: Markets the i-STAT and Piccolo systems used at the bedside for blood gas and basic chemistries. Broad incumbent in POC diagnostics that could expand its clinical menu to challenge HemoScreen in near-patient CBC.
Direct peers
- EKF Diagnostics: UK-based vendor of point-of-care analyzers including hemoglobin (Hemo Control) and other near-patient diagnostics. Compares to PixCell as a developer of small-footprint, decentralized hematology/POC devices for clinical and emerging-market customers.
- Sight Diagnostics: Israeli-AI blood diagnostics company whose OLO device delivers finger-prick, 5-part differential CBC at the point of care. Closest direct competitor to PixCell's HemoScreen, targeting the same small-sample, AI-vision-enabled POC hematology category.
- HemoCue (Radiometer / Danaher): Pioneer in capillary-sample, point-of-care hemoglobin testing, now part of Danaher/Radiometer. Most directly comparable on the finger-stick sample / decentralized POC value proposition PixCell pursues, even though HemoCue today primarily measures hemoglobin rather than full CBC.
- Boule Diagnostics: Swedish manufacturer of compact, low-volume hematology analyzers (e.g., Medonic, Swelab) widely used in smaller labs, point-of-care, and emerging markets. Directly comparable as a compact CBC analyzer vendor targeting decentralized settings.
- Diatron MI Zrt. Hungarian manufacturer of compact hematology analyzers (Abacus) for small-to-mid labs and POC environments. Competes head-to-head with HemoScreen in decentralized CBC analyzer procurement decisions globally.
Regional players
- HORIBA Medical: Japan/France-based hematology analyzer vendor (Pentra, Yumizen) with compact CBC instruments. Comparable as a vendor of small-footprint CBC analyzers competing for similar hospital and outreach lab deployments, particularly in Europe and APAC.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
PixCell Medical social profiles
Digital presencePixCell Medical compliance and trust
Trust signalCompliance3 records
PixCell Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
PixCell Medical leadership team
Management profileNumber of profiles
Profiles14 records
PixCell Medical funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PixCell Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PixCell Medical
What does PixCell Medical do?
PixCell Medical develops, manufactures, and markets the HemoScreen™ platform, a portable point-of-care hematology analyzer that performs a Complete Blood Count (CBC) with 5-part differential from a single drop of blood in approximately 5 minutes. The system consists of a reusable analyzer device and single-use factory-calibrated cartridges with integrated reagents, combining proprietary Viscoelastic Focusing (VEF) microfluidics, Lab-On-A-Cartridge design, and AI-powered machine vision for automated cell classification.
Is PixCell Medical a public or private company?
PixCell Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was PixCell Medical founded?
PixCell Medical was founded in 2009. It employs 51 to 100 people.
Where is PixCell Medical based?
PixCell Medical is headquartered in Yoqne`am `illit, Israel, in the Middle East region.
How does PixCell Medical make money?
Two revenue lines are on record. HemoScreen Analyzer Hardware is the primary driver. The others are single-Use Cartridges.
Who are PixCell Medical's main competitors?
Broad incumbents on record are Siemens Healthineers, Beckman Coulter (Danaher), Sysmex Corporation and Abbott Point of Care. Direct peers are EKF Diagnostics, Sight Diagnostics, HemoCue (Radiometer / Danaher), Boule Diagnostics and Diatron MI Zrt.. HORIBA Medical is listed as a regional player.
Does PixCell Medical have an API?
No public API is recorded for PixCell Medical.
What industry is PixCell Medical in?
PixCell Medical's product category is Point-of-Care Hematology Analyzers. Its primary akta.pro industry code is HLAHAOAD, Hematology POCT (CBC/hemoglobin/hematocrit), with a secondary code of HLAHAAAF, Flow Cytometry & Cellular Analysis Diagnostics. Its NAICS code is 334510 and its SIC code is 3841.